Parasites & vectors · 2025
Assessment of lotilaner (Credelio® CAT) for control of in-home Ctenocephalides felis infestations.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sutherland Cameron, Tomlinson Trey, Wilson Grace, Gray Amiah, Miller Kamilyah, Gin Taylor, Lashnits Erin, Li Yiyao, Kollasch Todd M, Locklear Casey L, Ryan William G, Canfield Michael, Herrin Brian H
Аннотация
BACKGROUND: Flea infestations remain a major issue in veterinary medicine. Highly effective flea control for dogs and cats remains the foundation for eliminating infestations from homes and improving skin conditions associated with flea-feeding.
METHODS: Homes with pet cats were screened by flea-history questionnaire. Qualifying homes were subselected into "high" (≥ 5 fleas on ≥ 1 cat, and ≥ 5 fleas collected in environmental flea traps over a 16-24 h period), "low" (< 5 fleas on all cats, < 5 in traps), and "no" homes (no evidence of fleas on cats or traps). All cats and dogs in a household were treated with a lotilaner oral tablet (Credelio® CAT and Credelio®, respectively) in weeks 0, 4, and 8. On-animal and trap counts were performed for: "high" at weeks 0, 1, 2, 4, 6, 8, and 11-12; "low" at week 0 and at approximately 2-week intervals through week 11-12; and "no" only at week 0. During each visit, one owner completed a pruritus assessment (PVAS) and a veterinary dermatologist assessed dermatologic lesions using the feline allergic dermatitis (SCORFAD) scale.
RESULTS: A total of 46 homes met inclusion criteria and completed the study: 19 "high" (35 cats); 17 "low" (27); and 10 "no" (14). By week 1, relative to pretreatment, there was a 99.3% reduction in flea counts on "high" cats, with 31 of 34 cats (91.2%) flea-free. By week 11-12, flea counts across all study cats and traps were zero. Prior to the first treatment, mean PVAS scores were: "high" 6.6; "low" 5.5; and "no" 1.9. By week 1 there was a significant decrease in mean PVAS score of cats from "high" homes to 2.9 (P < 0.0001), and mean week 11-12 scores were 0.5 and 0.8 for "high" and "low" homes, respectively. For SCORFAD, by week 11-12, relative to week 0, there was a significant decline in mean scores of cats from both "high" (8.0 to 1.7) (P < 0.0001) and "low" homes (3.3 to 0.9) (P < 0.0001).
CONCLUSIONS: Lotilaner was 100% efficacious in eliminating flea infestations from animals and their homes. The monthly lotilaner treatments of cats and dogs in flea-infested homes resulted in clinical resolution of pruritus and dermatologic lesions.
METHODS: Homes with pet cats were screened by flea-history questionnaire. Qualifying homes were subselected into "high" (≥ 5 fleas on ≥ 1 cat, and ≥ 5 fleas collected in environmental flea traps over a 16-24 h period), "low" (< 5 fleas on all cats, < 5 in traps), and "no" homes (no evidence of fleas on cats or traps). All cats and dogs in a household were treated with a lotilaner oral tablet (Credelio® CAT and Credelio®, respectively) in weeks 0, 4, and 8. On-animal and trap counts were performed for: "high" at weeks 0, 1, 2, 4, 6, 8, and 11-12; "low" at week 0 and at approximately 2-week intervals through week 11-12; and "no" only at week 0. During each visit, one owner completed a pruritus assessment (PVAS) and a veterinary dermatologist assessed dermatologic lesions using the feline allergic dermatitis (SCORFAD) scale.
RESULTS: A total of 46 homes met inclusion criteria and completed the study: 19 "high" (35 cats); 17 "low" (27); and 10 "no" (14). By week 1, relative to pretreatment, there was a 99.3% reduction in flea counts on "high" cats, with 31 of 34 cats (91.2%) flea-free. By week 11-12, flea counts across all study cats and traps were zero. Prior to the first treatment, mean PVAS scores were: "high" 6.6; "low" 5.5; and "no" 1.9. By week 1 there was a significant decrease in mean PVAS score of cats from "high" homes to 2.9 (P < 0.0001), and mean week 11-12 scores were 0.5 and 0.8 for "high" and "low" homes, respectively. For SCORFAD, by week 11-12, relative to week 0, there was a significant decline in mean scores of cats from both "high" (8.0 to 1.7) (P < 0.0001) and "low" homes (3.3 to 0.9) (P < 0.0001).
CONCLUSIONS: Lotilaner was 100% efficacious in eliminating flea infestations from animals and their homes. The monthly lotilaner treatments of cats and dogs in flea-infested homes resulted in clinical resolution of pruritus and dermatologic lesions.